N/A
N=100
Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population
Healthy Volunteers
Bottom Line
View on ClinicalTrials.gov: NCT02565784 ↗Enrolled (actual)
100
Serious AEs
5.0%
Results posted
Oct 2019
Primary outcome: Primary: Percentage of Participants Improved in "Global Facial Aesthetic Appearance" - Judged by Participant — 95 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Restylane (Device); Perlane (Device)
- Age
- Adult · 25+ yrs
- Sex
- Female
- Sponsor
- Galderma R&D
- Primary completion
- Dec 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Improved in "Global Facial Aesthetic Appearance" - Judged by Participant |
95 | — |
| SECONDARY Percentage of Participants Improved in Nasolabial Fold Severity (Merz Aesthetic Scale) - Judged by Investigator |
54; 65; 47; 46; 65; 62 | — |
| SECONDARY Percentage of Participants Improved in Upper Cheek Fullness - Judged by Investigator |
66; 67; 38; 43; 77; 78 | — |
Summary
The purpose of this study is to evaluate the safety and efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine after the first and second treatment when used for facial augmentation in Asian population.
Eligibility Criteria
Inclusion Criteria
- Subjects intent to undergo facial filler treatment for either volume loss or contouring
- Subjects requiring treatment in two to four of pre-defined areas in the face (upper cheeks, nasolabial folds, temples, nose and chin)
- Require 3-5 ml of investigational products to achieve a clinically meaningful improvement in appearance
- Facial appearance as Han Chinese
- Non-pregnant, non-breast feeding female
- Signed informed consent
Exclusion Criteria
- Previous facial surgery (e.g. rhinoplasty) or permanent implant in the area to be treated.
- History of chronic sinusitis or rhinitis (only applicable for subjects injected in the nose).
- Subjects who needs to use heavy glasses during the study (only applicable for subjects injected in the nose).
- Previous tissue augmenting therapy or contouring with permanent filler or fat injection in the facial area.
- Previous treatment with Hyaluronic acid (HA) fillers or Restylane Skinboosters in the facial area within 12 months before treatment.
- Previous treatment with non-HA fillers such as CaHA (Calcium Hydroxylapatite) or PLLA (Poly L-Lactic Acid) within 24 months before treatment.
- Previous revitalization with neurotoxin in the facial area within six (6) months before treatment.
- Previous tissue revitalization treatment with laser or light, mesotherapy, chemical peeling or dermabrasion in the facial area within six (6) months before treatment.
- Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).
Data sourced from ClinicalTrials.gov (NCT02565784). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.